Fisher & Paykel Healthcare Corporation Limited (NZS X:FPH. ASX:FPH) announced that today it introduced the latest additions to its range of flow generators at the Associated Professional Sleep Societies meeting in Chicago.
The new HC220LE and HC210 series flow generators, which are intended for use in the treatment of Obstructive Sleep Apnea (OSA), incorporate the next generation of Fisher & Paykel Healthcare’s in-house developed quiet motor and fan technology.
The HC220LE also features Fisher & Paykel Healthcare’s new Ambient Tracking™ Plus technology which controls humidity output with changing room temperature and airflow, providing greater humidity and comfort for the patient with minimal condensation. The HC220LE will be released to most of the company’s major international markets during June.
The HC210 flow generator, which will be available from early July, can be easily converted to fully integrated humidity including Ambient Tracking™ Plus technology. The company believes that a significant proportion of patients start their continuous positive airway pressure (CPAP) treatment without heated humidity, and subsequently add humidity if symptoms of dryness develop.
“We’re delighted to be offering these new products, which we are confident have the potential to further improve patient comfort and compliance with therapy”, said Michael Daniell, Fisher & Paykel Healthcare’s Managing Director and CEO. “The HC210 convertible flow generator broadens our product range and we believe it will give us the opportunity to participate in a significantly larger proportion of the OSA treatment market”.
Further information can be obtained by contacting Michael Daniell on +64 9 574 0161 or Tony Barclay on +64 9 574 0119 at Fisher & Paykel Healthcare Corporation Limited or by visiting the company’s website at www.fphcare.com
About Fisher & Paykel Healthcare
Fisher & Paykel Fisher Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Ends
Contact
|